Summary of Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Customer Information

Significant customer information is as follows:

	December 31,			March 31,
	2021			2021
Percentage of accounts receivable:
Customer C		78	%		35	%
Customer D		3	%		40	%
Customer F		11	%		0	%

	Three Months Ended December 31,						Nine Months Ended December 31,
	2021			2020			2021			2020
Percentage of revenue:
Customer C		17	%		31	%		19	%		21	%
Customer B		14	%		15	%		17	%		19	%

Summary Of Revenue By Category

The following table presents revenue by category:

	Three Months Ended December 31,										Nine Months Ended December 31,
	2021					2020					2021					2020
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)										(in thousands, except percentages)
PGS	$	38,367		67	%	$	44,094		79	%	$	130,705		76	%	$	119,381		77	%
Telehealth		7,673		14	%		—		0	%		7,673		5	%		—		0	%
Consumer services		46,040		81	%		44,094		79	%		138,378		81	%		119,381		77	%
Research services		10,851		19	%		11,383		21	%		32,956		19	%		35,909		23	%
Therapeutics		—		0	%		—		0	%		—		0	%		48		0	%
Total	$	56,891		100	%	$	55,477		100	%	$	171,334		100	%	$	155,338		100	%

Summary of Revenue by Region based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:

	Three Months Ended December 31,										Nine Months Ended December 31,
	2021					2020					2021					2020
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)										(in thousands, except percentages)
United States	$	41,741		73	%	$	40,074		72	%	$	120,706		70	%	$	108,502		70	%
United Kingdom		10,779		19	%		10,722		19	%		37,020		22	%		35,703		23	%
Canada		3,065		5	%		3,334		6	%		9,052		5	%		7,282		5	%
Other regions		1,306		2	%		1,347		2	%		4,556		3	%		3,851		2	%
International		15,150		27	%		15,403		28	%		50,628		30	%		46,836		30	%
Total	$	56,891		100	%	$	55,477		100	%	$	171,334		100	%	$	155,338		100	%

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended December 31,						Nine Months Ended December 31,
	2021			2020			2021			2020
	(in thousands)						(in thousands)
Segment Revenue
Consumer and Research Services	$	56,891		$	55,477		$	171,334		$	155,290
Therapeutics		—			—			—			48
Total Revenue	$	56,891		$	55,477		$	171,334		$	155,338
Segment Adjusted EBITDA
Consumer and Research Services Adjusted EBITDA	$	(31,967	)	$	(2,468	)	$	(33,232	)	$	(4,925	)
Therapeutics Adjusted EBITDA		(19,916	)		(15,051	)		(57,046	)		(38,886	)
Unallocated Corporate		(12,129	)		(7,796	)		(30,692	)		(21,554	)
Total Adjusted EBITDA	$	(64,012	)	$	(25,315	)	$	(120,970	)	$	(65,365	)
Reconciliation of net loss to Adjusted EBITDA
Net Loss	$	(89,396	)	$	(44,645	)	$	(147,946	)	$	(116,606	)
Adjustments
Interest (income), net		(76	)		(53	)		(213	)		(195	)
Other (income) / expense, net		(22	)		(445	)		(39	)		(1,318	)
Change in fair value of warrant liabilities		(3,695	)		—			(32,989	)		—
Income tax benefit		(3,512	)		—			(3,512	)		—
Depreciation and amortization		4,681			4,833			14,188			15,532
Amortization of acquired intangible assets		2,898			—			2,898			—
Stock-based compensation expense		17,409			14,995			37,473			37,222
Acquisition-related costs (1)		7,701			—			9,170			—
Total Adjusted EBITDA	$	(64,012	)	$	(25,315	)	$	(120,970	)	$	(65,365	)

(1)For the three and nine months ended December 31, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees related to the acquisition of Lemonaid Health.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended December 31,								Nine Months Ended December 31,
	2021				2020				2021				2020
	(in thousands, except percentages)								(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C(1)	$	9,676	17	%	$	17,451	31	%	$	33,123	19	%	$	31,965	21	%
Customer B(2)	$	8,069	14	%	$	8,554	15	%	$	29,281	17	%	$	30,221	19	%
Therapeutics Segment Revenue:
Customer E(2)	$	—	0	%	$	—	0	%	$	—	0	%	$	48	100	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the United Kingdom and Customer E is in a region other than the United States, United Kingdom, or Canada.